SYN.AI
Live / Applied — Statement of use — final refusal mailed (as of 15 Oct 2026)
Now
Refused — a final office action was mailed 15 Oct 2026.
A response is due by 15 Jan 2027; with no response the application is abandoned.
What this means for you
Not registered yet, but its 19 Jul 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98092280
- Mark type
- Word mark
- Filed
- 19 Jul 2023
- Published for opposition
- 03 Dec 2024
- Attorney of record
- Michelle P. Ciotola
Goods and services
- Class 042 — Scientific and technological services: Scientific research and custom synthesis in the nature of chemical engineering; scientific and clinical research in the field of medicine, pharmaceutical, nutraceuticals; scientific research and development; custom design and development of chemical reagents and biochemical assays; laboratory testing of materials; laboratory testing services for research purposes; testing of pharmaceuticals; chemical engineering; chemical analysis; drug discovery services; pharmaceutical drug development services; pharmaceutical product development; development of pharmaceutical preparations and medicines; scientific study and research in the field of reproduction, husbandry, and general health of companion animals, commercial livestock and wild animals; biotechnology research for determining the neuronal survival of molecules in animal models; research and development services in the field of antibodies, antibody technology; custom design and development of chemical reagents and biochemical assays; design, engineering, research, development and testing services in the field of polymeric materials, polymer synthesis, and materials customization for medical, scientific, and technological applications; toxicology services; toxicity analysis; toxicity testing for research purposes; scientific research in the nature of conducting clinical trials for others in the field of chemical engineering; scientific research in the nature of conducting clinical trials for others; scientific research in the nature of conducting clinical trials for pharmaceutical products; providing medical and scientific research information in the field of clinical trials; conducting early evaluations in the field of new pharmaceuticals; DNA analysis services for scientific research purposes; laboratory research in the field of gene expression; blood analysis services for scientific research purposes; analysis of human tissues for medical research; scientific research services relating to the isolation and cultivation of human tissues and cells; preparation of reports relating to scientific and technical research; biochemical analysis in the field of molecular biology; contract scientific research services relating to molecular sciences; biological cloning services; structural and functional analysis of genomes; scientific laboratory services; services of a chemical or biological scientific laboratory; laboratory research services relating to pharmaceuticals; scientific research and development and scientific research consultation in the fields of antibodies, antibody technology, chemistry, agrochemical pharmaceuticals, bioinformatics, biomedical, biologics, biotechnology, bio therapeutics, biology, biochemical, cell line, chemoinformatic, genetics and genetic engineering, gene expression systems, in vitro, inhalation pharmaceuticals, molecular sciences, micro-organisms, nutrition, ophthalmic, pharmacogenetics, pharmacokinetics, pharmacology, pharmaceuticals, polymer, peptide synthesis, protein, solid state characterization; toxicokinetic, scientific and technological services, namely, scientific research, development, design, testing, and engineering in the fields of antibody, API, biomolecules, cell bank characterization, chiral, chromosome aberration, clinical chemistry, cloning vector, cyclotides, DNA, flow cytometry, gas chromatography mass spectrometry, gene, immuno-pharmaceuticals, in vitro irritation, large molecule, liquid chromatography mass spectrometry, microbial, monomer, nano particle, natural products, peptides, proteins, RNA, supercritical fluid chromatography, small molecules and vaccines
- Class 044 — Medical, beauty and agricultural services: Medical diagnostic testing, monitoring and reporting services; preparation of reports relating to medical matters; medical testing of urine; medical pathology services
Owner
- SYNGENE INTERNATIONAL LIMITED, Bangalore, IN
- SYNGENE INTERNATIONAL LIMITED, Bangalore, IN
Prosecution history
- 15 Oct 2026 — NOTIFICATION OF FINAL REFUSAL EMAILED
- 15 Oct 2026 — FINAL REFUSAL E-MAILED
- 15 Oct 2026 — SU - FINAL REFUSAL - WRITTEN
- 18 Sept 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 18 Sept 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 18 Sept 2026 — ASSIGNED TO LIE
- 16 Sept 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 16 Jun 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 16 Jun 2026 — NON-FINAL ACTION E-MAILED
- 16 Jun 2026 — SU - NON-FINAL ACTION - WRITTEN
- 20 May 2026 — STATEMENT OF USE PROCESSING COMPLETE
- 14 Jan 2026 — USE AMENDMENT FILED
- 14 Jan 2026 — TEAS STATEMENT OF USE RECEIVED
- 15 Jul 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 14 Jul 2025 — SOU EXTENSION 1 GRANTED